Related Experiment Videos
Digital therapeutics use burden in patients with chronic diseases: a scoping review
1School of Nursing, Yanbian University, Yanji, China.
Objective:
To systematically map the available evidence on the potential use burden of digital therapeutics (DTx) and DTx-related therapeutic digital interventions in patients with chronic diseases and to inform clinical implementation and policy evaluation.
Methods:
PubMed, Web of Science (WOS), Cochrane Library, Embase, Wiley, Scopus, CNKI, WanFang Data, VIP, and SinoMed databases were searched from inception to April 28, 2026. Studies were screened according to the inclusion and exclusion criteria. Data were extracted on application areas, potential sources of DTx use burden, indirect burden-related evaluation indicators, and support strategies potentially relevant to reducing DTx use burden.
Results:
A total of 11 studies were included. DTx and DTx-related therapeutic digital interventions for patients with chronic diseases were mainly applied in diabetes, hypertension, coronary heart disease, chronic insomnia, cancer treatment support, and inflammatory bowel disease. None of the included studies used a dedicated instrument to directly measure DTx use burden. Instead, burden-related evidence was mainly derived from indirect indicators, including utilization and participation indicators, module and task completion indicators, data recording indicators, acceptability and satisfaction indicators, and technical problems and safety records. The task requirements, use difficulties, and indirect indicators reported in the included studies suggested five potential sources of DTx use burden: digital access burden, data recording burden, task completion burden, continuous use burden, and technical operation burden.
Conclusion:
Evidence on DTx use burden in patients with chronic diseases remains preliminary, and direct measurement of patients' subjective DTx use burden is limited. Future studies should combine patient-reported DTx use burden with objective usage data and documented reasons for discontinuation, and incorporate burden-related outcomes into implementation and policy evaluation to improve accessibility, continuity of use, equity, and implementation sustainability.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Drug Therapy
Antianxiety Medications
Therapeutic Drug Monitoring: Overview and Classification
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...